sellWeak cluster of 6
Holloway Jean F sold $12k of AORT
SVP, General Counsel at ARTIVION, INC.. 472 shares at an average of $25.29, traded Mar 5, 2025, filed Mar 6, 2025.
Warning score
30Value
$12k
472 shares
Holdings after
172,743
-0% from before
From 52-week low
+4%
low $24.33, close $25.37
From 52-week high
-20%
high $31.70, as of Mar 5, 2025
Score components
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price, last year
Rows in this filing
Every transaction in Form 4 0000784199-25-000045, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 5, 2025 | SOpen-market sale Common Stock | -472 | $25.29 | $12k | 172,743 | Mar 6, 2025 |
Related signals
Other insiders at ARTIVION, INC. and this insider’s other filings.
| Score | Side | Company | Insider | Value | Shares | Filed |
|---|---|---|---|---|---|---|
| 10Weak | sell 610b5-1 | AORT ARTIVION, INC. | Davis John E Chief Commercial Officer | $357k | 15,100 | |
| 12Weak | sell 610b5-1 | AORT ARTIVION, INC. | Holloway Jean F SVP, General Counsel | $426k | 18,020 | |
| 37Weak | sell 6 | AORT ARTIVION, INC. | Holloway Jean F SVP, General Counsel | $53k | 2,124 | |
| 36Weak | sell 6 | AORT ARTIVION, INC. | Stanton Marshall S. SVP, Clinical & MD Affair | $40k | 1,603 | |
| 38Weak | sell 6 | AORT ARTIVION, INC. | Davis John E Chief Commercial Officer | $65k | 2,618 | |
| 47Moderate | sell 6 | AORT ARTIVION, INC. | Berry Lance A Executive VP, CFO | $122k | 4,909 | |
| 35Weak | sell 6 | AORT ARTIVION, INC. | Horton Amy VP, Chief Accounting Officer | $26k | 1,048 | |
| 35Weak | sell 610b5-1 | AORT ARTIVION, INC. | Mackin James P President & CEO | $2.2M | 88,439 | |
| 39Weak | buy | AORT ARTIVION, INC. | SEMEDO ANTHONY B. director | $53k | 2,100 | |
| 41Moderate | sell 6 | AORT ARTIVION, INC. | Stanton Marshall S. SVP, Clinical & MD Affair | $128k | 4,687 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.